180 GPS Investments IC Ltd Buys New Shares in United Therapeutics Corporation $UTHR

Key Points

• 180 GPS Investments IC Ltd acquired 13,722 shares of United Therapeutics in the second quarter, worth approximately $7.4 million and representing 5.5% of its portfolio. Institutional investors and hedge funds collectively own 94.08% of UTHR.
• United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus estimate, although revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
• Analysts maintain a generally positive outlook, with 11 Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $646, above the stock’s reported $499.73 price.

180 GPS Investments IC Ltd bought a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,722 shares of the biotechnology company's stock, valued at approximately $7,435,000. United Therapeutics comprises 5.5% of 180 GPS Investments IC Ltd's portfolio, making the stock its 9th largest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in UTHR. Torren Management LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total value of $4,892,785.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $167,097,878.29. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company's stock, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 443,075 shares of company stock worth $241,508,744. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

UTHR stock opened at $499.73 on Monday. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The firm has a market cap of $21.43 billion, a P/E ratio of 17.88, a PEG ratio of 1.69 and a beta of 0.59. The company's 50-day simple moving average is $535.95 and its 200-day simple moving average is $536.15.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on UTHR. Weiss Ratings raised shares of United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source